Discovery of dual CDK4/6 and BRD4 inhibitor as apoptosis and autophagy inducers against NSCLC in vitro and in vivo

被引：0

作者：

Zhang, Yonglei ^{[1
,2
]}

Luo, Zhongwen ^{[1
,2
]}

Jiang, Yuhan ^{[1
,2
]}

Zheng, Long ^{[1
,2
]}

Ma, Liangliang ^{[1
,2
]}

Zheng, Yiwei ^{[1
,2
]}

Zou, Meiting ^{[1
,2
]}

Kong, Lingyi ^{[1
,2
]}

Wang, Xiaobing ^{[1
,2
]}

机构：

[1] China Pharmaceut Univ, Sch Tradit Chinese Pharm, Jiangsu Key Lab Bioact Nat Prod Res, Nanjing 210009, Peoples R China

[2] China Pharmaceut Univ, Sch Tradit Chinese Pharm, State Key Lab Nat Med, Nanjing 210009, Peoples R China

来源：

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2025年 / 290卷

关键词：

CDK4/6; BRD4; Non-small cell lung cancer; Apoptosis; Autophagy; DEPENDENT KINASE 4/6; CELL-PROLIFERATION; DRUG-THERAPY; BROMODOMAIN; TARGET; CANCER; POLYPHARMACOLOGY; DESIGN;

D O I：

10.1016/j.ejmech.2025.117495

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Target of cyclin dependent kinase (CDK) by inhibitors has demonstrated promising potential as a therapeutic agent for cancer. However, the efficacy of monotherapy on tumors is limited and there is an urgent need for combination therapy with other inhibitors. It has been reported that restoring bromodomain-containing protein 4 (BRD4) resensitivity to tumor cells by inhibiting CDK4/6 is a potential therapeutic strategy. In this study, we present the design and optimization of dual CDK4/6 and BRD4 inhibitors, among which B15 exhibited potent and selective inhibition of both targets in vitro, and significant antiproliferative effects in non-small cell lung cancer (NSCLC) cells. Importantly, it also showed good pharmacokinetic properties in rats, meanwhile, B15 effectively inhibited tumor growth in vivo (TGI = 85.3 %) without causing significant toxicity. Overall, our results introduce a promising strategy of dual CDK4/6 and BRD4 inhibitors for the treatment of NSCLC.

引用

页数：22

共 50 条

[41] Synergistic Efficacy of CDK4/6 Inhibitor Abemaciclib and HDAC Inhibitor Panobinostat in Pancreatic Cancer Cells [J].

Bhutkar, Shraddha ;

Yadav, Anjali ;

Patel, Himaxi ;

Barot, Shrikant ;

Patel, Ketan ;

Dukhande, Vikas V. .

CANCERS, 2024, 16 (15)

[42] CDK4/6 inhibitor enhances the radiosensitization of esophageal squamous cell carcinoma (ESCC) by activating autophagy signaling via the suppression of mTOR [J].

Qin, Wen-Jun ;

Su, Yi-Ge ;

Ding, Xiao-Long ;

Zhao, Ren ;

Zhao, Zhi-Jun ;

Wang, Yan-Yang .

AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2022, 14 (03) :1616-1627

[43] Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma [J].

Rader, JulieAnn ;

Russell, Mike R. ;

Hart, Lori S. ;

Nakazawa, Michael S. ;

Belcastro, Lili T. ;

Martinez, Daniel ;

Li, Yimei ;

Carpenter, Erica L. ;

Attiyeh, Edward F. ;

Diskin, Sharon J. ;

Kim, Sunkyu ;

Parasuraman, Sudha ;

Caponigro, Giordano ;

Schnepp, Robert W. ;

Wood, Andrew C. ;

Pawel, Bruce ;

Cole, Kristina A. ;

Maris, John M. .

CLINICAL CANCER RESEARCH, 2013, 19 (22) :6173-6182

[44] CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy [J].

Nardone, Valerio ;

Barbarino, Marcella ;

Angrisani, Antonio ;

Correale, Pierpaolo ;

Pastina, Pierpaolo ;

Cappabianca, Salvatore ;

Reginelli, Alfonso ;

Mutti, Luciano ;

Miracco, Clelia ;

Giannicola, Rocco ;

Giordano, Antonio ;

Pirtoli, Luigi .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (16)

[45] Discovery of a New CDK4/6 and PI3K/AKT Multiple Kinase Inhibitor Aminoquinol for the Treatment of Hepatocellular Carcinoma [J].

Xia, Zhong-Kun ;

Wang, Wei ;

Qiu, Jian-Ge ;

Shi, Xi-Nan ;

Li, Hong-Jian ;

Chen, Rong ;

Ke, Kun-Bin ;

Dong, Chao ;

Zhu, Ying ;

Wu, Shi-Guo ;

Zhang, Rong-Ping ;

Meng, Zhuo-Ran ;

Zhao, Hui ;

Gu, Peng ;

Leung, Kwong-Sak ;

Wong, Man-Hon ;

Liu, Xiao-Dong ;

Zhou, Feng-Mei ;

Zhang, Jian-Ying ;

Yao, Ya-Ting ;

Wang, Si-Jia ;

Zhang, Chun-Yang ;

Qin, Yan-Ru ;

Lin, Marie Chia-Mi ;

Jiang, Bing-Hua .

FRONTIERS IN PHARMACOLOGY, 2021, 12

[46] Dual inhibition of BRD4 and PI3K by SF2523 suppresses human prostate cancer cell growth in vitro and in vivo [J].

Shen, Gang ;

Jiang, Minjun ;

Pu, Jinxian .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 495 (01) :567-573

[47] Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma [J].

Perumal, Deepak ;

Kuo, Pei-Yu ;

Leshchenko, Violetta V. ;

Jiang, Zewei ;

Divakar, Sai Krishna Athaluri ;

Cho, Hearn Jay ;

Chari, Ajai ;

Brody, Joshua ;

Reddy, M. V. Ramana ;

Zhang, Weijia ;

Reddy, E. Premkumar ;

Jagannath, Sundar ;

Parekh, Samir .

CANCER RESEARCH, 2016, 76 (05) :1225-1236

[48] Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells [J].

Fiskus, Warren ;

Sharma, Sunil ;

Qi, Jun ;

Valenta, John A. ;

Schaub, Leasha J. ;

Shah, Bhavin ;

Peth, Karissa ;

Portier, Bryce P. ;

Rodriguez, Melissa ;

Devaraj, Santhana G. T. ;

Zhan, Ming ;

Sheng, Jianting ;

Iyer, Swaminathan P. ;

Bradner, James E. ;

Bhalla, Kapil N. .

MOLECULAR CANCER THERAPEUTICS, 2014, 13 (05) :1142-1154

[49] Cisplatin Cytotoxicity in Human Testicular Germ Cell Tumor Cell Lines Is Enhanced by the CDK4/6 Inhibitor Palbociclib [J].

Rossini, Elisa ;

Bosatta, Valentina ;

Abate, Andrea ;

Fragni, Martina ;

Salvi, Valentina ;

Basnet, Ram Manohar ;

Zizioli, Daniela ;

Bosisio, Daniela ;

Piovani, Giovanna ;

Valcamonico, Francesca ;

Mirabella, Giuseppe ;

Berruti, Alfredo ;

Memo, Maurizio ;

Sigala, Sandra .

CLINICAL GENITOURINARY CANCER, 2021, 19 (04) :316-324

[50] Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors [J].

Shao, Mingfeng ;

He, Linhong ;

Zheng, Li ;

Huang, Lingxiao ;

Zhou, Yuanyuan ;

Wang, Taijing ;

Chen, Yong ;

Shen, Mingsheng ;

Wang, Fang ;

Yang, Zhuang ;

Chen, Lijuan .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (17) :4051-4055

← 1 2 3 4 5 →